

# COVID-19 and Mpox Situational Report in the ASEAN Region

— ASEAN BioDiaspora Virtual Center (ABVC)



## ASSOCIATION OF SOUTHEAST ASIAN NATIONS



## ASEAN BIODIASPORA VIRTUAL CENTER (ABVC)



MINISTRY OF HEALTH  
REPUBLIC OF INDONESIA

## GLOBAL PARTNERS





# Table of Contents

<b>COVID-19</b>	<b>1</b>
<a href="#">Highlights and Situation Overview</a>	1
<a href="#">Global Update</a>	1
<a href="#">Regional Update</a>	1
<a href="#">Vaccine Update</a>	2
<a href="#">Research Update</a>	2
<a href="#">Travel Update</a>	3
<a href="#">COVID-19 Cases and Deaths Table</a>	5
<a href="#">COVID-19 Cases in ASEAN Region Table</a>	5
<a href="#">COVID-19 Cases in Asia-Pacific Region Table</a>	5
<a href="#">Epi curve Among ASEAN Countries</a>	7
<a href="#">ASEAN Weekly New Cases and New Deaths</a>	8
<a href="#">Vaccination Status in ASEAN</a>	9
<a href="#">ASEAN Outlook Assessment</a>	10
<b>Mpox</b>	<b>11</b>
<a href="#">Map of Mpox Cases Globally</a>	11
<a href="#">Mpox Daily Trend Globally</a>	12
<a href="#">Highlights and Situation Overview</a>	13
<a href="#">Mpox Cases in ASEAN Region Table</a>	13
<a href="#">Mpox Cases in Asia-Pacific Region Table</a>	13
<a href="#">Top 5 Countries with Most Mpox Cases Globally</a>	13
<a href="#">Mpox Cases per Region</a>	14
<b>References</b>	<b>15</b>



## COVID-19: Highlights and Situation Overview

### Global Update

- **Worldwide**, there have been over 659 million cases and over 6 million deaths attributed to COVID-19.
- The **World Health Organization (WHO)** said in its weekly update that COVID-19 cases dropped 7% by last week compared to the previous 28 days, adding that COVID-19 cases have declined or remained stable in all world regions. Deaths, however, were up by 20%, reflecting rises in three regions: the Western Pacific, the Americas, and the Eastern Mediterranean. The United States and Japan reported the most deaths. The WHO said the increase doesn't include the nearly 60,000 deaths reported from China over the past month, because it is waiting for China to provide a breakdown by province. In its variant update, the WHO said BA.5 is still dominant at the global level, making up 70.5% of sequences. It added that BA.2 and its descendant lineages are increasing, while recombinants show a stable pattern. [\[Full report\]](#)
- The **European Centre for Disease Prevention and Control (ECDC)** said in its weekly update that the overall epidemiologic picture in the European region is improving after markers rose in December.<sup>2</sup> The report also noted that the BQ.1 subvariant makes up nearly half of cases.<sup>2</sup> XBB subvariant levels, including XBB.1.5, are still in the single digits.<sup>2</sup> The ECDC also warned about lingering holiday effects on data gathering. And it said though the COVID situation appears to be improving, just over 1,600 deaths were reported in the region in the second week of January, with the biggest impact in older age-groups.<sup>2</sup> [\[Full article\]](#)
- **USA:** The Navajo Nation ended its COVID-19 mask mandate on January 20 (Friday), almost three years after it was introduced.<sup>3</sup> The Navajo Nation covers parts of Arizona, New Mexico, and Utah and is home to about 250,000 people.<sup>3</sup> The reservation has entered "low risk" status in terms of hospital usage for COVID patients.<sup>3</sup> In the latest update, it recorded 80,539 cases and 2,00 deaths.<sup>3</sup> According to President Nygren, the Navajo Nation is one of the last jurisdictions in the country to lift a mask mandate.<sup>3</sup> However, indoor mask is still required to early childhood education centers, primary and secondary schools, nursing homes, healthcare facilities, and people who have COVID-19 symptoms, test positive, or were exposed.<sup>3</sup> [\[Full article\]](#)
- The **US Centers for Disease Control and Prevention (CDC)** said in its weekly report that the 7-day average for new daily cases is 47,459, down nearly 24% compared to a week ago.<sup>1</sup> For the week ending January 16, hospitalizations recorded about 5,000 new patients each day, down 16.4% from the previous week.<sup>1</sup> However, the CDC's new respiratory virus hospitalization tracker, called RESP-NET, suggests that COVID-19 hospitalizations are likely increasing as of December 31 among adults ages 65 and older.<sup>1</sup> Meanwhile, the 7-day average of new fatalities was 565, down 6.1% from the week before.<sup>1</sup> Other tracking metrics such as test positivity, wastewater sampling, and community levels has also declined.<sup>1</sup> In its variant update today, the CDC estimated the more transmissible and immune-evasive XBB.1.5 Omicron subvariant makes up nearly 50% of sequences, up from 43% the previous week, while levels of other subvariants are declining.<sup>1</sup> The XBB.1.5 subvariant is dominant in the Northeast and Mid-Atlantic states and makes up a growing proportion of subvariants in all other regions.<sup>1</sup> [\[Full article\]](#)

### Regional Update

- **Malaysia:** According to Health Director-General Tan Sri Dr Noor Hisham Abdullah, admissions of COVID-19 patients to health facilities per 100,000 population fell 8.6% in



the third epidemiological week 2023 (ME 3/2023) from Jan 15 to 21, compared to the previous week.<sup>8</sup> According to him, admissions of patients in categories one through five to public hospitals per 100,000 people fell by 28.6% last week compared to ME 2/2023.<sup>8</sup> According to Dr. Noor Hisham, there has also been a decrease in the number of positive cases tracked by COVID-19 Assessment Centres (CAC) around the country.<sup>8</sup> [\[Full article\]](#)

- **Philippines:** The daily average of new coronavirus disease 2019 (Covid-19) cases in the country reduced by 35% from January 16 to 22, according to the Department of Health (DOH) on January 23.<sup>9</sup> According to the DOH's most current case bulletin, daily infections reduced to 270 from 417 from Jan. 9 to 15. In addition, the DOH reported 1,891 additional cases and 104 confirmed deaths.<sup>9</sup> Seven of the new deaths occurred between January 9 and 22, 2023.<sup>9</sup> So far, the country has recorded over 4.07 million coronavirus cases and over 65,694 fatalities from the virus.<sup>9</sup> During the same week, four cases were added to the total number of severe and critical infections, which fell to 432 from 567 the previous week.<sup>9</sup> Only 16.1%, or 370, of the 2,299 intensive care unit (ICU) beds are in use, while 19.1%, or 3,509, of the 18,410 non-ICU beds are in use.<sup>9</sup> [\[Full article\]](#)

## Vaccine Update

- **Bharat Biotech** will launch its intranasal COVID-19 vaccine iNCOVACC on January 26. The company said that it had already received an approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India. According to the company, the nasal route has excellent potential for vaccination due to the organized immune system of the nasal mucosa. Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection, and transmission. The nasal vaccine can be taken after six months of the second dose.
- **Malaysia's National Pharmaceutical Regulatory Agency (NPRA)** has approved an application from Solution Biologics Sdn Bhd, regarding the extension of the shelf life of the COVID-19 vaccine, Convidecia Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Solution for Injection. NPRA senior director (Pharmaceutical Services) said that the new approved shelf life is from 15 months to 18 months when stored at a temperature of 2 degrees Celsius to 8 degrees Celsius. The extension of the shelf life involves the MAL21066050AZ vaccine, manufactured at CanSino Biologics Inc, China, and MAL22126013ASZ manufactured at Solution Biologics Sdn Bhd, Malaysia. According to the statement, the approval of this shelf-life extension is retrospective, meaning that this approval also applies to all stocks, including all stocks that have been received before this shelf-life extension was approved.

## Research Update (Published and peer-reviewed studies)

- The study on **First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2** evaluated the safety, immunogenicity, and tolerability of ABNCoV2 in SARS-CoV-2 in participants aged 18 and 55 years who had no record of SARS-CoV-2 infection or COVID-19 vaccination were eligible.<sup>4</sup> After vaccination with two ABNCoV2 doses, RBD-specific (receptor binding domain) CD4<sup>+</sup> T cells were elicited.<sup>4</sup> The team noted that the phenotype associated with the responding CD4<sup>+</sup> T cells was primarily positive for interferon (IFN)- $\gamma$ , with the majority of cells, co-expressing CD137 and tumor necrosis factor (TNF).<sup>4</sup> The 50  $\mu$ g dose of the vaccination generated a more significant CD4<sup>+</sup> T-cell response than the 25  $\mu$ g dose and a lower CD4<sup>+</sup> T-cell response than the 70  $\mu$ g dose.<sup>4</sup> Also, RBD-specific CD8<sup>+</sup> T cells showed a marginal increase. Approximately 14 days following the second vaccination, significant in-vitro activity was shown by live virus





neutralization tests.<sup>4</sup> All ABNCoV2 dosages examined with and without adjuvant MF59 elicited 50% plaque reduction neutralization test (PRNT50) titers against FR-4286, a SARS-CoV-2 B.1 isolate that represented ancestral variants.<sup>4</sup> The study findings indicated that ABNCoV2 displayed considerable tolerance and elicited substantial virus-neutralizing antibody responses following the second vaccination in healthy SARS-CoV-2 naive individuals.<sup>4</sup> [\[Full text\]](#)

- The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and resulting COVID19 (coronavirus disease 2019) pandemic have required mass diagnostic testing, often taking place in testing sites within hospitals, clinics, or at satellite locations.<sup>5</sup> This study, ***SARS-CoV-2 Aerosol and Surface Detections in COVID-19 Testing Centers and Implications for Transmission Risk in Public Facing Workers***, aimed to establish the potential of SARS-CoV-2 aerosol transmission and to identify junctures during testing that result in increased viral exposure.<sup>5</sup> Aerosol and surface samples were collected from highly trafficked areas within each location, such as check-in areas, waiting areas, and specimen collection areas.<sup>5</sup> These were examined for the presence of SARS-CoV-2 RNA from locations within Nebraska Medicine COVID-19 testing and vaccine clinics.<sup>5</sup> In addition, tests administered per day and patient positivity statistics were obtained from clinics and positivity and test positivity rates were obtained from the surrounding community.<sup>5</sup> Linear regressions between environmental observations and clinic test data, as well as comparisons between clinic positivity data and surrounding community data were performed.<sup>5</sup> SARS-CoV-2 RNA detection in aerosol samples was shown to correlate with clinic operation and patient infection, as well as with community infection findings.<sup>5</sup> Additionally, SARS-CoV-2 RNA was detected in surface samples collected from clinics.<sup>5</sup> The presence of SARS-CoV-2 RNA in aerosols in these clinics supports the continued use of respiratory protection and sanitization practices for healthcare workers, and other workers with public facing occupations.<sup>5</sup> [\[Full text\]](#)
- This cohort study, ***Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection***, identified characteristics associated with persistent post-COVID-19 symptoms and described post-COVID-19 medical encounters using data from the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases With Pandemic Potential (EPICC) study implemented in the US military health system (MHS). Data from 1832 MHS beneficiaries aged 18 years or older who tested positive for SARS-CoV-2 from February 28, 2020, through December 31, 2021, were analyzed.<sup>6</sup> Data showed that the risk of reporting symptoms for 28 or more days after COVID-19 onset was significantly higher in participants who were unvaccinated at the time of infection and those who reported moderate or severe acute illness symptoms.<sup>6</sup> At 6 months after onset, participants had significantly higher risk of pulmonary, diabetes, neurological, and mental health encounters vs pre-infection baseline.<sup>6</sup> The findings suggest that COVID-19 is associated with increased health care encounters through 6 months after infection; vaccination was associated with lower risk of long term COVID-19 symptoms.<sup>6</sup> [\[Full text\]](#)

## Travel Update

- **Indonesia:** Island of Bali welcomed its first direct flight from China in nearly three years on January 23, potentially putting an end to the resort island's economically damaging COVID-19 suspension.<sup>7</sup> The Associated Press said that at least 210 people were on board the chartered jet operated by Indonesia's Lion Air, which took off from Shenzhen in Guangdong province.<sup>7</sup> The trip came as a result of the Chinese government's decision to ease travel restrictions beginning January 8, raising hopes for the resuscitation of Southeast Asia's once-thriving tourism economies in time for this week's Lunar New Year vacation, when many Chinese nationals travel abroad.<sup>7</sup> While Indonesia as a whole is not as reliant on tourism as other countries in the region, particularly Thailand, few regions



in Southeast Asia are as dependant as Bali.<sup>7</sup> Tourism accounts for approximately 5% of the Indonesian economy (vs approximately 20% in Thailand), but accounts for approximately 80% of the Bali economy.<sup>7</sup> [\[Full article\]](#)



## COVID-19 Cases and Deaths as of 23 January 2023

- As of 23 January 2023 (1PM, GMT+7), worldwide, there were **659,985,415** confirmed cases, including **6,735,718** deaths. Globally, Case Fatality Rate (CFR) was **1.2%**.
- 35,562,391 confirmed cases** of COVID-19 have been reported in the **ASEAN Region**.
- The Case Fatality Rate in the **ASEAN Region** is range between **0.1 to 3.1%**.

### COVID-19 cases in ASEAN region

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN REGION	Brunei Darussalam	10 Mar 20	22-Jan-23	274,217	-	225	-	63,288	450,404	445,929	338,987	99.32
	Cambodia	27 Jan 20	22-Jan-23	138,676	-	3,056	-	841	15,244,858	14,609,937	10,433,215	87.13
	Indonesia	02 Mar 20	22-Jan-23	6,728,065	218	160,781	4	2,486	203,657,535	172,693,321	67,952,274	62.68
	Lao PDR	24 Mar 20	22-Jan-23	217,944	2	758	-	3,040	5,888,649	5,222,417		69.36
	Malaysia	25 Jan 20	22-Jan-23	5,034,830	309	36,932	-	15,759	28,125,159	27,536,547	17,054,185	81.14
	Myanmar	23 Mar 20	22-Jan-23	633,801	2	19,490	-	1,173	34,777,314	27,545,329	2,227,351	50.84
	Philippines	30 Jan 20	22-Jan-23	4,071,963	423	65,694	14	3,766	78,369,243	73,937,435	21,341,197	63.98
	Singapore	23 Jan 20	22-Jan-23	2,210,681	269	1,720	-	38,760	5,161,990	5,120,768	4,440,289	90.84
	Thailand	13 Jan 20	22-Jan-23	4,725,885	-	33,792	-	6,788	57,005,497	53,486,086	32,143,431	74.6
	Vietnam	23 Jan 20	22-Jan-23	11,526,329	11	43,186	-	11,949	90,450,881	85,848,363	57,452,750	87.43
ASEAN COUNTRIES				35,562,391	1,234	365,634	18	147,849	519,131,530	466,446,132	213,383,679	

\*There have been no tests reported in the last 14 days in the ASEAN Region.

### COVID-19 cases in Asia-Pacific region

REGION	COUNTRY/ TERRITORY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASIA-PACIFIC REGION	Afghanistan	24-Feb-20	20-Jan-23	208,084	-	7,864	-	547	11,606,705	10,894,509		26.49
	Australia	25-Jan-20	18-Jan-23	11,254,721	-	17,706	-	43,878	22,236,871	21,655,312	19,762,423	82.73
	Bangladesh	08-Mar-20	20-Jan-23	2,037,408	-	29,441	-	1,250	150,629,515	131,182,263	65,672,743	76.63
	Bhutan	05-Mar-20	17-Jan-23	62,577	-	21	-	8,200	699,116	677,669	634,641	86.61
	People's Republic of China*		22-Jan-23	12,707,782	21,930	34,605	0	78,486	1,339,515,531	1,304,360,996	213,862,616	89.7
	Cook Islands	17-Feb-22	20-Jan-23	6,988	-	2	-	32,673	15,084	14,715	10,209	86.4
	Fiji	18-Mar-20	20-Jan-23	68,808	-	883	-	7,732	711,658	640,668	170,563	68.91
	French Polynesia	12-Mar-20	04-Jan-23	77,957	-	649	-	27,913	190,765	186,059	112,237	60.75
	Guam	15-Mar-20	20-Jan-23	60,585	-	415	-	36,215	158,611	144,042		85.49
	India	30-Jan-20	22-Jan-23	44,681,921	140	530,733	3	3,270	1,027,271,126	951,428,765	223,737,969	67.14





	Japan	16-Jan-20	19-Oct-22	21,858,528	-	46,014	-	17,312	104,603,775	103,213,313	168,546,442	83.27
	Kiribati	25-Jan-22	21-Jan-23	4,991	-	18	-	4,244	96,184	73,888	23,419	56.3
	Maldives	07-Mar-20	18-Jan-23	185,708	-	311	-	34,976	399,151	385,081	167,187	73.52
	Marshall Islands	26-Oct-20	02-Jan-23	15,554	-	17	-	26,456	43,310	34,694		44.63
	Micronesia	11-Jan-21	21-Jan-23	22,676	-	58	-	19,924	84,729	71,253		69.64
	Mongolia	10-Mar-20	21-Jan-23	1,007,855	-	2,179	-	31,250	2,272,965	2,175,617	1,044,337	64.02
	Nepal	24-Jan-20	22-Jan-23	1,001,076	1	12,020	-	3,499	27,678,479	24,159,118	8,951,403	79.09
	New Caledonia	17-Mar-20	17-Jan-23	79,785	-	314	-	27,722	192,213	184,656	101,655	63.68
	New Zealand	28-Feb-20	16-Jan-23	2,157,933	-	3,676	-	43,887	4,300,097	4,138,926	3,523,903	79.82
	Niue	03-Sep-21	20-Jan-23	730	-	-	-	33,703	1,636	1,634	1,224	83.71
	Northern Mariana Islands	28-Mar-20	20-Jan-23	13,485	-	41	-	23,569	46,567	43,873		84.61
	Pakistan	26-Feb-20	22-Jan-23	1,576,176	9	30,640	-	728	154,665,740	131,368,973	49,551,181	55.71
	Palau	31-May-21	21-Jan-23	5,986	-	9	-	33,241	20,750	18,497		85.9
	Papua New Guinea	21-Mar-20	21-Dec-22	46,663	-	669	-	532	369,998	310,717	32,384	3.06
	Samoa	18-Nov-20	20-Jan-23	16,022	-	29	-	8,129	191,163	177,721	79,360	79.91
	Solomon Islands	03-Oct-20	24-Nov-22	24,575	-	153	-	3,669	343,821	254,352	27,783	35.12
	Republic of Korea**	20-Jan-20	22-Jan-23	29,999,529	16,624	33,219	26	58,016	44,867,046	44,448,105	41,325,954	85.78
	Sri Lanka	27-Jan-20	20-Jan-23	671,976	-	16,825	-	3,082	17,143,761	14,752,827	8,220,002	67.57
	Timor Leste	21-Mar-20	21-Jan-23	23,409	-	138	-	1,810	878,845	790,466	315,249	58.93
	Tonga	05-Nov-21	12-Jan-23	16,590	-	13	-	15,877	91,949	77,464	38,331	72.49
	Türkiye	10-Mar-20	12-Dec-22	17,041,315	-	101,487	-	20,426	57,941,051	53,176,961	41,425,329	62.31
	Vanuatu	11-Nov-20	06-Jan-23	12,014	-	14	-	4,006	144,824	131,697	16,996	40.31
	Wallis et Futuna	17-Oct-20	31-Dec-22	3,427	-	7	-	21,385	7,136	6,794	3,742	58.59
	ASIA PACIFIC			146,952,834	38,704	870,170	29	677,605	2,969,420,172	2,801,181,625	847,359,282	

\*includes cases from Hong Kong (SAR), Macau (SAR), and Taiwan (Province of China).

\*\*Republic of Korea – South Korea


- **477,470,190 confirmed cases** of COVID-19 have been reported in other **4 regions** (other than ASEAN and Asia-Pacific countries):

REGION	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED
AFRICA	13,024,475	454	259,388	-	248,198	483,101,815	397,425,845	65,784,702
AMERICAS	191,550,237	2,084	2,942,921	67	1,237,196	835,416,524	731,862,763	495,078,311
EUROPE	250,208,868	151,211	2,058,457	1,296	2,102,836	569,613,832	541,035,869	383,258,265
MIDDLE EAST	22,686,610	1,792	239,148	16	215,727	144,725,527	130,012,457	60,202,629
TOTAL	477,470,190	155,541	5,499,914	1,379	3,803,957	2,032,857,698	1,800,336,934	1,004,323,907



# COVID-19 Epi curve among ASEAN Countries:

From January 1, 2022 to January 22, 2023




Cumulative cases of COVID-19 in the ASEAN Region as of January 22, 2023 (Report generated by ASEAN Biodiaspora Virtual Center)

\*Data from Bluedot Insights, cases may differ from how data is reported in countries and other authorities. Data may be subject to retrospective correction by national authorities.



# ASEAN Weekly COVID-19 New Cases and New Deaths



From January 1, 2022 to January 22, 2023





# ASEAN COVID-19 Vaccination Status



as of 22 January 2023





# ASEAN COVID-19 Outlook Assessment

as of 20 January 2023

  <b>ASEAN MEMBER STATE</b>	<p>At least <b>65% of the total population has a level of immunity</b> to COVID-19; either recovered from COVID-19 or have been vaccinated with at least one dose of a COVID-19 vaccine.</p>		<p><b>Case levels are generally low</b> (a 7-day rolling average number of daily new cases that is &lt;10 cases per 100,000, with each day's past-14-day test positivity is consistently &lt;5%).</p>	<p><b>Government Policy</b> on containment and health (strictness and comprehensiveness in COVID-19 related government policies)</p>
	% of Total population fully vaccinated / boosted	Population vaccinated/ day (7-day average)	Daily cases/ 100,000	Containment and health index score - Oxford COVID-19 Government Response Tracker (OxCGRT)
Brunei Darussalam	≥90.0/75.5	Unknown	51.79	31.0/100
Cambodia	≥90.0/62.2	Unknown	0.01	31.5/100
Indonesia	66.1/24.7	Unknown	0.10	54.2/100
Lao PDR	77.3/ND	Unknown	0.03	61.6/100
Malaysia	84.5/50.2	0%/day	0.96	51.8/100
Myanmar	52.1/4.1	Unknown	0.01	69.1/100
Philippines	71.5/18.5	Unknown	0.22	55.4/100
Singapore	≥90.0/78.8	0%/day	6.31	58.9/100
Thailand	77.7/44.8	Unknown	0.20	31.5/100
Vietnam	≥90.0/58.5	Unknown	0.03	43.5/100


All of the countries have achieved the Population vaccinated/ day (7-day average) except Vietnam.





# Mpox (Monkeypox) Cases Reported Globally

as of January 22, 2023








## Mpox Daily Trend Globally

as of January 20, 2023





## Mpox: Highlights and Situation Overview

- As of 23 January 2023 (1PM, GMT+7), worldwide, there were **91,400** confirmed cases, including **230** deaths. Globally, Case Fatality Rate (CFR) was **0.25%**.
- 42 confirmed cases** in the ASEAN region, with CFR of **0%**.
- 91,358 confirmed cases** of Mpox have been reported in other **5 regions** (other than ASEAN region):

### Mpox cases in ASEAN region

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Indonesia	1	-	-	0.00%
Philippines	4	-	-	0.00%
Singapore	21	-	-	0.00%
Thailand	12	-	-	0.00%
Vietnam	4	-	-	0.00%
<b>ASEAN Total</b>	<b>42</b>	<b>-</b>	<b>-</b>	<b>0.00%</b>

### Mpox cases in Asia-Pacific region

Country/Territory	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Australia	144	-	-	0.00%
Hong Kong (SAR)	1	-	-	0.00%
India	23	-	1	5.00%
Japan	9	1	-	0.00%
New Caledonia	1	-	-	0.00%
New Zealand	40	-	-	0.00%
People's Republic of China*	9	-	-	0.00%
Republic of Korea	4	-	-	0.00%
Sri Lanka	2	-	-	0.00%
<b>Asia-Pacific Total</b>	<b>233</b>	<b>1</b>	<b>1</b>	<b>0.43%</b>

\*People's Republic of China – including Hongkong (SAR), Macao (SAR), and Taiwan (Province of China)

### Top 5 countries with most mpox cases globally

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
United States of America	30,026	35	23	0.08%
Brazil	10,645	-	15	0.14%
Spain	7,513	-	3	0.04%
Democratic Republic of Congo	5,114	-	120	2.35%
France	4,114	-	-	0.00%



## Mpox cases per region

REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	6,783	-	161	2.37%
AMERICAS	57,808	46	63	0.11%
ASEAN	42	-	-	0.00%
ASIA PACIFIC	233	1	1	0.43%
EUROPE	26,169	-	5	0.02%
MIDDLE EAST	319	-	-	0.00%
<b>TOTAL</b>	<b>91,400</b>	<b>47</b>	<b>230</b>	<b>0.25%</b>



## References

1. "Covid Data Tracker Weekly Review." *Centers for Disease Control and Prevention*, Centers for Disease Control and Prevention, 20 Jan. 2023, <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html>.
2. "Weekly COVID-19 Country Overview." *European Centre for Disease Prevention and Control*, 2 Jan. 2023, <https://www.ecdc.europa.eu/en/covid-19/country-overviews>.
3. "Navajo Nation Covid-19 Dashboard." *Navajo Nation Department of Health*, 19 Jan. 2023, <https://ndoh.navajo-nsn.gov/COVID-19/Data>.
4. Smit, Merel J, et al. "First-in-Human Use of a Modular Capsid Virus-like Vaccine Platform: An Open-Label, Non-Randomised, Phase 1 Clinical Trial of the SARS-COV-2 Vaccine abncov2." *The Lancet Microbe*, 18 Jan. 2023, [https://doi.org/10.1016/s2666-5247\(22\)00337-8](https://doi.org/10.1016/s2666-5247(22)00337-8).
5. Stein, Sarah J., et al. "SARS-COV-2 Aerosol and Surface Detections in COVID-19 Testing Centers and Implications for Transmission Risk in Public Facing Workers." *International Journal of Environmental Research and Public Health*, vol. 20, no. 2, 5 Jan. 2023, p. 976., <https://doi.org/10.3390/ijerph20020976>.
6. Richard, Stephanie A., et al. "Persistent Covid-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-COV-2 Infection." *JAMA Network Open*, vol. 6, no. 1, 18 Jan. 2023, <https://doi.org/10.1001/jamanetworkopen.2022.51360>.
7. Strangio, Sebastian. "Bali Welcomes Chinese Flight after Long Covid-19 Hiatus." *The Diplomat*, The Diplomat, 23 Jan. 2023, <https://thediplomat.com/2023/01/bali-welcomes-chinese-flight-after-long-covid-19-hiatus/>.
8. "Drop in Covid-19 Admissions Last Week – Health DG." *The Malaysian Reserve*, 23 Jan. 2023, <https://themalaysianreserve.com/2023/01/23/drop-in-covid-19-admissions-last-week-health-dg/>.
9. Montemayor, Ma. Teresa. "Daily Average of New Covid-19 Cases down by 35%." *Philippine News Agency*, Philippine News Agency, 23 Jan. 2023, <https://www.pna.gov.ph/articles/1193347>.



Report generated by  
**ASEAN Biodiaspora Virtual Center (ABVC)**  
 in collaboration with **Bluedot Inc.**

Email: [support@biodiaspora.org](mailto:support@biodiaspora.org)

Facebook: <https://facebook.com/ASEANBiodiaspora>

Instagram: <https://instagram.com/ASEANBiodiaspora>



In partnership with  
**Canada**